3-(4-Fluorobenzamido)benzoic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(4-Fluorobenzamido)benzoic acid
• 英文别名: 3-[(4-fluorobenzoyl)amino]benzoic acid
• 化学式: C₁₄H₁₀FNO₃
• mdl: MFCD00433323
• 分子量: 259.23
• InChiKey: RQZOSWYDLJDFRS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Acylated indanyl amines and their use as pharmaceuticals
  申请人：——

  公开号：US20030055093A1

  公开（公告）日：2003-03-20

  The present invention relates to acylated indanyl amines according to the general formula (I) 1 wherein R 1 -R 4 have the meanings given in the description, A is CH 2 , CHOH or CH—(C 1 -C 3 -alkyl), B is CH 2 or CH—(C 1 -C 3 -alkyl), and R 5 is an aryl or heteroaryl group, possibly substituted by the substituents listed in the description. These compounds are useful in the upregulation of endothelial nitric oxide synthase (eNOS), and may therefore be useful for the manufacture of medicaments for the treatment of cardiovascular diseases, stable or unstable angina pectoris, coronary heart disease, Prinzmetal angina, acute coronary syndrome, heart failure, myocardial infarction, stroke, thrombosis, peripheral artery occlusive disease, endothelial dysfunction, atherosclerosis, restenosis, endothelial damage after PTCA, hypertension, essential hypertension, pulmonary hypertension, secondary hypertension, renovascular hypertension, chronic glomerulonephritis, erectile dysfunction, ventricular arrhythmia, diabetes or diabetes complications, nephropathy or retinopathy, angiogenesis, asthma bronchiale, chronic renal failure, cirrhosis of the liver, osteoporosis, restricted memory performance, a restricted ability to learn, or for the lowering of cardiovascular risk of postmenopausal women or after intake of contraceptives.

  本发明涉及通式（I）中的酰化的茚基胺，其中R1-R4具有描述中给出的含义，A为CH2、CHOH或CH—（C1-C3-烷基），B为 或CH—（C1-C3-烷基），R5为芳基或杂芳基，可能被描述中列出的取代基取代。这些化合物在上调内皮型一氧化氮合酶（eNOS）方面有用，因此可能用于制造用于治疗心血管疾病、稳定或不稳定心绞痛、冠心病、普林兹梅塔心绞痛、急性冠状综合征、心力衰竭、心肌梗死、中风、血栓形成、周围动脉闭塞性疾病、内皮功能障碍、动脉粥样硬化、再狭窄、PTCA后内皮损伤、高血压、原发性高血压、肺动脉高压、继发性高血压、肾血管性高血压、慢性肾小球肾炎、勃起功能障碍、室性心律失常、糖尿病或糖尿病并发症、肾病或视网膜病变、血管生成、支气管哮喘、慢性肾功能衰竭、肝硬化、骨质疏松症、记忆力受限、学习能力受限，或用于降低绝经后妇女或口服避孕药后心血管风险。
• ACYLATED INDANYL AMINES AND THEIR USE AS PHARMACEUTICALS
  申请人：STROBEL Hartmut

  公开号：US20070082897A1

  公开（公告）日：2007-04-12

  The present invention relates to acylated indanyl amines according to the general formula (I) wherein R 1 —R 4 have the meanings given in the description, A is CH 2 , CHOH or CH—(C 1 -C 3 -alkyl), B is CH 2 or CH—(C 1 -C 3 -alkyl), and R 5 is an aryl or heteroaryl group, possibly substituted by the substituents listed in the description. These compounds are useful in the upregulation of endothelial nitric oxide synthase (eNOS), and may therefore be useful for the manufacture of medicaments for the treatment of cardiovascular diseases, stable or unstable angina pectoris, coronary heart disease, Prinzmetal angina, acute coronary syndrome, heart failure, myocardial infarction, stroke, thrombosis, peripheral artery occlusive disease, endothelial dysfunction, atherosclerosis, restenosis, endothelial damage after PTCA, hypertension, essential hypertension, pulmonary hypertension, secondary hypertension, renovascular hypertension, chronic glomerulonephritis, erectile dysfunction, ventricular arrhythmia, diabetes or diabetes complications, nephropathy or retinopathy, angiogenesis, asthma bronchiale, chronic renal failure, cirrhosis of the liver, osteoporosis, restricted memory performance, a restricted ability to learn, or for the lowering of cardiovascular risk of postmenopausal women or after intake of contraceptives.

  本发明涉及通式（I）的酰化吲哚基胺，其中R1-R4具有描述中给出的含义，A为CH2，CHOH或CH-（C1-C3-烷基），B为 或CH-（C1-C3-烷基），而R5为芳基或杂芳基基团，可能被描述中列出的取代基所取代。这些化合物有助于上调内皮型一氧化氮合酶（eNOS），因此可能用于制造用于治疗心血管疾病、稳定或不稳定型心绞痛、冠心病、普林兹梅塔尔心绞痛、急性冠状动脉综合征、心力衰竭、心肌梗死、中风、血栓形成、周围动脉闭塞症、内皮功能障碍、动脉粥样硬化、再狭窄、PTCA后的内皮损伤、高血压、原发性高血压、肺动脉高压、继发性高血压、肾血管性高血压、慢性肾小球肾炎、勃起功能障碍、室性心律失常、糖尿病或糖尿病并发症、肾病或视网膜病变、血管生成、支气管哮喘、慢性肾衰竭、肝硬化、骨质疏松症、受限制的记忆表现、受限制的学习能力或降低绝经后妇女或口服避孕药后的心血管风险。
• INSECTICIDAL COMPOUNDS
  申请人：Renold Peter

  公开号：US20100048652A1

  公开（公告）日：2010-02-25

  A compound of formula (I): wherein A 1 , A 2 , A 3 , A 4 , R 1 , R 2 , R 3 , R 4 , G 1 , G 2 , Q 1 , Y 1 , Y 2 , and Y 4 are as defined in claim 1 ; or salts or N-oxides thereof. Furthermore, the present invention relates to processes and intermediates for preparing compounds of formula (I), to insecticidal, acaricidal, molluscicidal and nematicidal compositions comprising them and to methods of using them to combat and control insect, acarine, mollusc and nematode pests.

  化合物的式子（I）：其中A1，A2，A3，A4，R1，R2，R3，R4，G1，G2，Q1，Y1，Y2和Y4如权利要求1所定义的；或其盐或N-氧化物。此外，本发明涉及制备式（I）化合物的过程和中间体，包括它们的杀虫剂，杀螨剂，杀软体动物剂和杀线虫剂组合物以及使用它们来对抗和控制昆虫，螨虫，软体动物和线虫害的方法。
• Novel Acylaminobenzamide Derivatives
  申请人：Mihara Jun

  公开号：US20110201603A1

  公开（公告）日：2011-08-18

  The present invention relates to novel Acylaminobenzamide derivatives represented by the following formula (I) and use thereof as pesticides: wherein V represents an aromatic ring group of V1 to V5 described in the detailed description, Q represents an aromatic ring group of Q1 to Q7 described in the detailed description, G 1 and G 2 represent O or S, R 1 represents hydrogen, alkyl, haloalkyl, alkoxy, haloalkoxy, phenyl or a heterocyclic group and R 2 and R 3 represent hydrogen, alkyl, haloalkyl, alkylcarbonyl, haloalkylcarbonyl, alkoxycarbonyl or haloalkoxycarbonyl.

  本发明涉及一种新型的Acylaminobenzamide衍生物，其化学式如下（I），以及其作为杀虫剂的用途：其中V代表详细描述中的V1至V5的芳香环基团，Q代表详细描述中的Q1至Q7的芳香环基团，G1和G2代表O或S，R1代表氢、烷基、卤代烷基、烷氧基、卤代烷氧基、苯基或杂环基，R2和R3代表氢、烷基、卤代烷基、烷基羰基、卤代烷基羰基、烷氧基羰基或卤代烷氧基羰基。
• [EN] SELECTIVE BUTYRYLCHOLINESTERASE INHIBITOR OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF<br/>[FR] INHIBITEUR SÉLECTIF DE LA BUTYRYLCHOLINESTÉRASE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION<br/>[ZH] 选择性丁酰胆碱酯酶抑制剂或其可药用的盐、其制备方法及用途
  申请人：UNIV CHINA PHARMA

  公开号：WO2021042410A1

  公开（公告）日：2021-03-11

  公开了具有通式(I)的选择性丁酰胆碱酯酶抑制剂或其可药用的盐、其制备方法及用途。以丁酰胆碱酯酶抑制活性、选择性的筛选以及对神经细胞的毒性为载体来检验治疗阿尔茨海默氏病的疗效，尤其是中重度阿尔茨海默氏病，发现其具有良好的体外靶标活性、极高的选择性以及药物安全性，可作为进一步开发通过选择性抑制丁酰胆碱酯酶来发挥治疗阿尔茨海默氏病作用的先导物质。